CPRX Stock Risk & Deep Value Analysis
Catalyst Pharmaceuticals Inc
DVR Score
out of 10
What You Need to Know About CPRX Stock
We analyzed Catalyst Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CPRX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
CPRX Risk Analysis & Red Flags
What Could Go Wrong
The speculative takeover interest from Angelini Pharma could dissipate without a formal offer, leading to a significant de-rating of the stock as the M&A premium evaporates, with organic growth alone proving insufficient to drive substantial upside from current valuations.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Low
Competitive
Medium
Execution
Medium
Regulatory
Medium
Red Flags
- ⚠
Reliance on acquisitions for significant growth acceleration, rather than a deep, innovative early-stage pipeline.
- ⚠
The current valuation may already price in some M&A premium, making it vulnerable to any negative news on that front.
- ⚠
Absence of granular balance sheet metrics (e.g., current/quick ratio, debt-to-equity) in the provided brief, though overall financial health is strong.
Upcoming Risk Events
- 📅
Q1 2026 earnings miss consensus estimates or provide weak future guidance
- 📅
Takeover discussions fail or are officially called off
- 📅
Increased competitive pressure or generic entry for FIRDAPSE after patent expiry
When to Reconsider
- 🚪
If takeover talks are officially halted or denied by the company
- 🚪
If Q1 2026 earnings fall significantly short of consensus expectations or 2026 guidance is reduced
- 🚪
If the stock price breaks and holds below $25, indicating a loss of key support.
Unlock CPRX Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Catalyst Pharmaceuticals is a financially robust and strategically adept specialty pharma company, leveraging its commercial infrastructure for rare diseases. With strong profitability, shareholder-friendly capital allocation via share repurchases, and recent M&A interest, it offers significant potential for value realization, particularly through an acquisition premium. While organic 10x growth is challenging, the current valuation provides a compelling entry for investors seeking exposure to a well-managed company with multiple upside catalysts.
Is CPRX Stock Undervalued?
Unlock the full AI analysis for CPRX
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CPRX Price Targets & Strategy
12-Month Target
$38.00
Bull Case
$45.00
Bear Case
$25.00
Valuation Basis
19x forward P/E applied to estimated FY26 EPS of $2.00, reflecting M&A speculation and organic growth.
Entry Strategy
Consider dollar-cost averaging in the $27-$29 range, ideally on any market weakness or if the stock consolidates near its recent support levels.
Exit Strategy
Consider taking initial profits around $38-$40; implement a stop-loss order at $25 to protect against downside if M&A speculation fades or fundamentals deteriorate.
Portfolio Allocation
3-7% for moderate risk tolerance
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is CPRX Financially Healthy?
Valuation
P/E Ratio
16.38
Forward P/E
17.42
PEG Ratio
0.85
Profitability
Gross Margin
85.19%
Operating Margin
43.77%
Net Margin
36.39%
Return on Equity
24.32%
Revenue Growth
19.78%
EPS
$1.68
Balance Sheet
Current Ratio
6.08
Quick Ratio
5.70
Cash Flow
Free Cash Flow
$129.40M
Other
Beta (Volatility)
0.74
Does CPRX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Stable to Expanding
Moat Sources
2 Identified
The moat is primarily driven by patent protection and orphan drug exclusivity for its commercialized assets. These protections offer a durable, albeit time-limited, competitive advantage. Switching costs for patients on established therapies for chronic conditions also contribute. The moat expands through successful M&A and pipeline development, extending the portfolio of protected assets.
Moat Erosion Risks
- •Patent expirations for key drugs leading to generic competition
- •Development of superior or more convenient treatment options by competitors
- •Regulatory changes affecting orphan drug designations or pricing policies.
CPRX Competitive Moat Analysis
Sign up to see competitive advantages
CPRX Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bullish, fueled by strong financial performance and takeover rumors.
Institutional Sentiment
Positive, with a consensus 'Strong Buy' rating and high institutional ownership (~79.2%). BofA reiterated rating amid M&A report.
Insider Activity (Form 4)
No specific Form 4 filings reporting insider buys/sells in available data for the last 90 days.
Options Flow
Normal options activity.
Earnings Intelligence
Next Earnings
2026-05-11
Surprise Probability
Medium
Historical Earnings Pattern
Historically, specialty pharma companies like Catalyst can experience volatility around earnings, with stock price reactions often tied to guidance and specific drug performance rather than just bottom-line beats.
Key Metrics to Watch
Competitive Position
Top Competitor
ACAD (Acadia Pharmaceuticals)
Market Share Trend
Gaining/Stable, particularly in its niche rare disease markets, driven by successful acquisitions and commercialization of FIRDAPSE and AGAMREE.
Valuation vs Peers
Trading generally in line with profitable specialty pharma peers on a TTM P/E basis (17.4x), potentially at a slight discount given its strong profitability and growth metrics. Peers with more extensive pipelines may command higher multiples.
Competitive Advantages
- •Intellectual property and orphan drug designations for key products (FIRDAPSE, AGAMREE)
- •Established commercial infrastructure and expertise in rare neurological diseases
- •Strategic M&A capabilities to acquire and integrate valuable assets
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive CPRX Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings release on May 11, 2026 (after market close)
- •Execution and progress of the $200 million share repurchase program
- •Further news or confirmation regarding takeover interest from Angelini Pharma
Medium-Term (6-18 months)
- •Successful integration of acquired assets and expansion of FIRDAPSE/AGAMREE sales
- •Potential new indications or regulatory approvals for existing pipeline assets
- •Additional strategic M&A activities to broaden the rare disease portfolio
Long-Term (18+ months)
- •Establishment as a leading player in specific rare neurological disease markets
- •Sustained cash flow generation to fund organic growth and further acquisitions
- •Long-term patent protection and market exclusivity for key drugs
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CPRX?
- ✓
Confirmation or denial of M&A talks by official company statements
- ✓
Acceleration in FIRDAPSE/AGAMREE sales beyond expectations
- ✓
Positive updates on any early-stage pipeline assets or new therapeutic area entries
Bull Case Analysis
See what could go right with Premium
Competing with CPRX
See how Catalyst Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Catalyst Pharmaceuticals Inc CPRX | $3.5B | 4.0 | 16.4 | — | 36.4% | 19.8% |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Catalyst Pharmaceuticals Inc Makes Money
Catalyst Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing innovative medicines for patients suffering from rare neurological and neuromuscular diseases. The company generates revenue primarily by selling its approved prescription drugs, such as FIRDAPSE for Lambert-Eaton Myasthenic Syndrome (LEMS) and AGAMREE for Duchenne muscular dystrophy. This business model relies on identifying niche patient populations with high unmet medical needs, securing intellectual property rights and orphan drug designations for their treatments, and then commercializing these therapies through a specialized sales and support infrastructure to patients and healthcare providers.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Catalyst Pharmaceuticals Inc (CPRX)?
As of May 3, 2026, Catalyst Pharmaceuticals Inc has a DVR Score of 4.0 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Catalyst Pharmaceuticals Inc?
Catalyst Pharmaceuticals Inc's market capitalization is approximately $3.5B..
What is the risk level for CPRX stock?
Our analysis rates Catalyst Pharmaceuticals Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CPRX?
Catalyst Pharmaceuticals Inc currently has a price-to-earnings (P/E) ratio of 16.4. This is in line with broader market averages.
Is Catalyst Pharmaceuticals Inc's revenue growing?
Catalyst Pharmaceuticals Inc has reported revenue growth of 19.8%. The company is showing strong top-line momentum.
Is CPRX stock profitable?
Catalyst Pharmaceuticals Inc has a profit margin of 36.4%. This indicates strong profitability.
How often is the CPRX DVR analysis updated?
Our AI-powered analysis of Catalyst Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 3, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CPRX (Catalyst Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.